Poster presentations (as of 9/18/23)

**Poster Session A**
Thursday, October 12 | 12:30 pm-4:00 pm
Level 2, Exhibit Hall D

A001: *Mapping the interaction between C-type lectin domain group 14A and Multimerin 2*. Aleen Baber, University of Birmingham, Birmingham, United Kingdom.

A002: *The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies*. Danielle M. Burgenske, Mayo Clinic, Rochester, MN United States.

A003: *A novel treatment strategy for high-risk and relapse/refractory hepatoblastoma*. Andres F. Espinoza, Baylor College of Medicine, Houston, TX United States.


A005: *Preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers in humanized mouse models*. Glenn Smits, EPO GmbH, Berlin, Germany.


A007: *Preclinical Bone Metastasis Technology Platform – Predictive evaluation of Experimental Therapies on Bone Metastasis*. Tiina E. Kähkönen, OncoBone, Kiviniemi, Finland.

A008: *An in vivo screening platform based on Ba/F3 kinase-engineered cell lines for discovering next-generation kinase inhibitors*. Stephanie Wang, Kyinno Biotechnology, Waltham, MA United States.


A011: *NRBF2 induces radioresistance by increasing autophagy mediated metabolite replenishment in glioblastoma*. Eunguk Shin, Pusan National University, Busan, Korea, Republic of.

A012: *Role of STX1A in mediating Cathepsin G’s entry into human colorectal cancer cells*. Valery Rozen, Michigan State University College of Human Medicine, Grand Rapids, MI United States.


A017: Computer simulation and quantification of the mass-action law-base pharmacodynamics parameters for anti-cancer and anti-viral therapeutics for single drugs and their combinations. Ting-Chao David Chou, PD Science, LLC, Paramus, NJ United States.

A018: Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations. Eldad D. Shulman, National Cancer Institute, Bethesda, MD United States.

A019: elf4A and PDCD4 expression in TNBC underlies sensitivity to natural product translation inhibitor. Alagu Subramanian, Baylor University, Waco, TX United States.

A020: Reversing triple negative breast cancer stem cells by disrupting the Notch signaling pathway via BCL6 targeting. Massimo Di Nicola, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

A021: Screening of Novel therapeutic markers for Ovarian Cancer Stem Cells. Sang Hyun Min, K-MEDI hub, Daegu, Korea, Republic of.


A023: Preclinical development of PKMYT1 and WEE1 inhibitor combinations. David Gallo, Repare Therapeutics, St-Laurent, QC Canada.

A024: Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors in chromosomally unstable solid tumor lines. Sukanya Patra, Satya Pharma Innovations, Hyderabad, India.

A025: Cytostatic effects and expression modulations in cell cycle genes by a 3rd generation alkylphospholipid (erufosine) in liver and lung cancer cells. Asim Pervaiz, Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan.

A026: Synthesis and structure-activity studies of DNA- and RNA-binding nucleopeptides with a cell penetrating potential. Stefano Tomassi, University of Naples Federico II, Naples, Italy.

A027: A photoactivatable microtubule-targeting rigidin prodrug. Alexander Kornienko, Texas State University, San Marcos, TX United States.


A030: Treatment with sustained-release anagrelide reduces tumor volume and has antiproliferative effects in a patient-derived GIST xenograft mouse model. Harri Sihto, University of Helsinki, Helsinki, Finland.

A031: Development of poly lactic acid based biodegradable nanoparticles for co-delivery of pirarubicin and gemcitabine for synergistic anti-tumor efficacy. Priya Gupta, IIT Delhi, New Delhi, India.

A032: Cell membrane coated- Biomimetic biodegradable nanoparticles for tumor targeted delivery of THP-doxorubicin using polylactic acid based redox responsive polymer. Harshdeep Kaur, IIT-Delhi, New Delhi, India.

A033: Anti-proliferative effects of lentinan, a beta-glucan from shiitake mushroom (lentinula edodes). Titus Sombuor, Texas Woman's University, Denton, TX United States.

A034: Synthesis and biological activities of a novel series of “combi-molecules” designed to delay metabolic dealkylation prior to crossing the blood brain barrier in the context of optimizing their potency against glioblastoma multiforme. Ana Belen Fraga-Timiraos, The Research Institute of the McGill University Health Center, Montreal, QC Canada.

A036: A subset of lung adenocarcinomas defined by high-level ERBB2 amplification is vulnerable to HER2-targeted therapy. Igor Odintsov, Brigham and Women's hospital, Boston, MA United States.


A039: Carnitine palmitoyltransferase IA: An emerging potential metabolic target to counteract HER2-targeted therapy resistance in HER2-positive breast cancer. Serenella M. Pupa, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

A040: Characterization of a humanized monoclonal antibody targeting cancer-expressed EGFR. Tamara G. Fernandes Costa, CCR, NCI, NIH, Bethesda, MD United States.


A042: Targeting vulnerabilities arising from global DNA hypomethylation in cancer. Pallabi Mustafi, Fred Hutchinson Cancer Center, Seattle, WA United States.


A045: EZH2 inhibition re-sensitizes drug resistant triple-negative breast cancer PDX models to Eribulin. Kathryn Bozek, McGill University, Montreal, QC Canada.
A046: Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers. Susanta Samajdar, Aurigene Oncology Ltd, Bengaluru, India.

A047: Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers. Susanta Samajdar, Aurigene Oncology Limited, Bangalore, India.

A048: Novel murine models of ARID1A and PBRM1-deficient cholangiocarcinoma for preclinical discovery and development. Caitlin B. Conboy, Division of Medical Oncology, Mayo Clinic, Rochester, MN United States.


A050: A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors. Apostolia Tsimeridou, University of Texas M.D. Anderson Cancer Center, Houston, TX United States.

A051: Discovery and characterization of a p300-selective degrader demonstrates potent anti-tumor activity in preclinical models of prostate cancer. Mike Russell, Proteovant Therapeutics, King of Prussia, PA United States.


A053: Interleukin-16 is a novel target to prevent age-associated epigenetic changes leading to malignant transformation associated with ovarian high-grade serous carcinoma (HGSOC). Jessica Ramirez, Rush University Medical Center, Chicago, IL United States.

A054: Small molecule microarray lysate screen identifies bromodomain ligands that target the MYC transcription regulatory network. Emily B. Cohen, Kronos Bio, Cambridge, MA United States.


A066: TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice. Ismail Meraz, University of Texas MD Anderson Cancer Center, Houston, TX United States.

A068: Site-specific modification of nanobodies for ImmunoPET of Liver Cancer utilizing Self-labeling nanobody-tag pair (SLANT) technology. Stanley Fayn, NCI/NIH, Bethesda, MD United States.

A069: Generation of Llama-Derived Phage Display Library Specific to Hepatocellular Carcinoma Tumor Targets. Divya Nambiar, NIH/NCI, Bethesda, MD United States.

A070: Olaparib enhances radiation-induced Type I interferon and sensitizes pancreatic cancer to PD-L1 immune checkpoint inhibition. Victoria M. Valvo, University of Michigan, Ann Arbor, MI United States.


A072: Ghrelin deletion reduces mammary tumor growth and enhances response to immunotherapy. William H. Walker II, West Virginia University, Morgantown, WV United States.

A074: Discovery of WTX-330, a clinical stage conditionally activated IL-12 INDUKINE™ therapeutic with potent antitumor activity in murine syngeneic tumor models resistant to checkpoint blockade. Andres Salmeron, Werewolf Therapeutics, Inc., Watertown, MA United States.

A076: Discovery and characterization of a novel, immunoproteasome activator that modulates the immunopeptidome, increases MHC class I antigenic presentation and enhances antitumor immunity. Priyanka S. Rana, Case Western Reserve University School of Medicine, Cleveland, OH United States.


A078: Intratumoral administration of ultra high-concentration Nitric Oxide (UNO) and anti-PD-1 treatment leads to high tumor regression rates and prolonged survival in tumor-bearing mice. Yana Epshtein, Beyond Cancer, Rehovot, Israel.

A079: FHD286 is a BRG1/BRM ATPase inhibitor showing efficacy in NSCLC models and is applicable to NSCLC patients both as a single agent treatment and in combination with current standards of care. Oliver Mikse, Foghorn Therapeutics, Cambridge, MA United States.


A083: A breast cancer PDX-derived cell lines preclinical platform as a tool for pharmacological screening and functional studies. Olivier Déas, XenTech, Evry, France.

A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRAS\textsuperscript{G12C} inhibitors that bind in the switch II pocket. Bin Wang, BridgeBio Oncology Therapeutics, South San Francisco, CA United States.

A085: BI KRAS\textsuperscript{multi}, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target. Antonio Tedeschi, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

A086: NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers. Bradley Quade, Nested Therapeutics, Inc., Cambridge, MA United States.

A087: BI KRAS\textsuperscript{multi}, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models. David H. Peng, The University of Texas MD Anderson Cancer Center, Houston, TX United States.


A090: Preclinical efficacy of BDTX-4933, a brain-penetrant, orthosteric RAF inhibitor, targeting oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations. Yoon-Chi Han, Black Diamond Therapeutics, New York, NY United States.


A092: Determinants of sensitivity to BI KRAS\textsuperscript{multi} inhibitor using high-throughput in-vitro drug screens. Fiorella Schischlik, Boehringer Ingelheim, Vienna, Austria.

A093: Deep Cyclic Inhibition of the MAPK pathway with IMM-6-415, alone and in combination with encorafenib, demonstrates anti-tumor activity and tolerability in RAF mutant tumors in vivo. Anna Travesa, Immuneering, San Diego, CA United States.

A094: Preclinical characterization of HMPL-415, a second-generation SHP2 inhibitor. Jia Hu, HUTCHMED Limited, Shanghai, China (Mainland).

A096: RAS mutation status predicts activity of the SHP2 inhibitor TNO155 in RAS-pathway driven fusion-negative rhabdomyosarcoma. Andrew Baker, Johns Hopkins School of Medicine, Baltimore, MD United States.

A097: HBI-2438, HUYABIO selective KRAS\textsuperscript{G12C} inhibitor with BBB penetration, inhibited tumor growth in a metastatic brain model as single agent and also displayed synergy in combination with HBI-2376 (HUYABIO SHP2 inhibitor) in a CRC PDX model. Farbod Shojaei, HUYABIO International, San Diego, CA United States.


A099: Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS driven tumors. Srikant Viswanadha, Satya Pharma Innovations, Hyderabad, India.

A100: Large-scale cell line profiling of small molecule MAPK pathway inhibitors identifies important differences between therapeutics acting on the same biochemical target. Jeffrey J. Kooijman, Oncolines B.V., Oss, Netherlands.

A101: Novel KRAS inhibitors suppress MAPK pathway signalling and display potent anti-proliferative activity across a broad range of KRAS mutant cell lines. Inder Bhamra, Redx Pharma, Macclesfield, United Kingdom.

A103: Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile. Kate Brown, National Institutes of Health, National Cancer Institute, Bethesda, MD United States.

A105: Pharmacological inhibition of nicotinamide adenine dinucleotide (NAD\textsuperscript{+}) production enzyme nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular survival, energy metabolism, and tumor growth in neuroblastoma (NB) models. Sophia Varriano, NCI-NIH, Bethesda, MD United States.

A106: Pharmacological activation of CLIP3 reduces radioresistance by suppressing stemness and glycolysis in glioblastoma. Hyunkoo Kang, Pusan National University, Busan, Korea, Republic of.

A107: Diacylglycerol kinase B mediates radioresistance by regulating mitochondrial lipotoxicity in glioblastoma. Haksoo Lee, Pusan National University, Busan, Korea, Republic of.

A108: Metabolic oriented treatment: Efficacy of sr59230a 3-adrenergic receptor antagonist, and sr plus buformin\textsuperscript{®} in Ewing sarcoma. Cristina Banella, Meyer Children’s Hospital IRCCS, Florence, Italy.

A109: Targeting pyrimidine biosynthesis as a metabolic vulnerability in brain metastasis. Shawn C. Chafe, McMaster University, Hamilton, ON Canada.


A111: Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Abdelrahman Yousef, The University of Texas MD Anderson Cancer Center, Houston, TX United States.
A112: A Semi-Supervised Approach to Classify Atypical BRAF Mutations to Identify Effective Targeted Therapies in Colorectal Cancer. Abhinav B. Madduri, University of Texas MD Anderson Cancer Center, Houston, TX United States.

A113: National Multidisciplinary Tumor Board improves diagnostic stratification and therapeutic management in Cancers of Unknown Primary. Ivan Bieche, Institut Curie, Paris, France.


A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): Final results, preclinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2). Helen L. Robbins, University of Birmingham, Birmingham, United Kingdom.

A116: TSC1 mutant bladder cancer is characterized by a TSC-associated gene expression signature due to TFE3 transcriptional activity. Magdalena Losko, Brigham and Women's Hospital, Harvard Medical School, Boston, MA United States.


A120: Differential roles of PI3K catalytic kinases in glioblastoma's chemoresistance. Zhi Sheng, Fralin Biomedical Research Institute, Roanoke, VA United States.

A121: Temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Jibran Ahmed, The University of Texas MD Anderson Cancer Center, Houston, TX United States.


A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials. Ezra Rosen, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY United States.

A124: Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment. James Miles, HAWK Biosystems, Derio, Spain.

A126: Characterization of proteasome stress response reporter mammalian cell lines for the discovery of DDI2 inhibitors in multiple myeloma. Cameron VanCleave, Brigham and Women’s Hospital, Boston, MA United States.


A131: Cumulative burden of fatty liver and kidney cancer in young-aged men: A national population-based study. Hee Yeon Lee, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of.

A132: Pathological Analysis of a Newly Established Immunocompetent Mice with Full Hpv16 Genome Integration. Xue Li, UNC at Chapel Hill, Chapel Hill, NC United States.

A134: Predicting activity of IMM-1-104 as single agent and in combination for patients with RAS or RAF mutant tumors. Brett Hall, Immunoeering, San Diego, CA United States.

A135: Are survival benefits of new drugs in combinations due to modest benefits in most patients or large benefits in few patients? Haeun Hwangbo, The University of North Carolina at Chapel Hill, Chapel Hill, NC United States.


A141: Preclinical pharmacokinetic (PK) and tumor growth inhibition (TGI) modeling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoral administration for solid cancer. David Hodson, Physiomics plc, Oxford, United Kingdom.


A143: Coupling fragment-based screening with targeted protein degradation and genetic rescue to identify and explore the function of a non-canonical pocket on eIF4E. Paul A. Clarke, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, United Kingdom.

A145: CBFβ supports global protein translation in osteosarcoma and may provide a new therapeutic target. Nicholas A. Oldberg, University of California, Davis, CA United States.


A147: A HER2 targeted polylysine dendrimer nanoparticle radiotheranostic demonstrates excellent tumor accumulation, rapid clearance from circulation, and promising performance in PET-CT imaging. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.


A150: Effects of radioimmunotherapy on human and canine osteosarcoma microenvironment. Sabeena Giri, University of Saskatchewan, Saskatoon, SK Canada.

A151: Establishing assays to investigate combinations of fractioned radiotherapy with DNA damage response agents in vitro and in vivo to enable investigation of radiosensitization and improved anti-tumour responses. Graeme E. Walker, Sygnature Discovery, Macclesfield, United Kingdom.


A154: PDLIM2 is required for regulating inflammation and cellular redox levels in mouse colorectal epithelial model. Rosemary O'Connor, University College Cork, Cork, Ireland.


A158: Rational Development of Synergistic Therapies Alongside BMI1 Inhibition for Group 3 Medulloblastoma. David Bakhshinyan, McMaster University, Hamilton, ON Canada.


A160: The FGFR axis is a potential radiosensitization target. Takahiro Oike, Gunma University, Maebashi, Japan.

A162: A Comprehensive Platform for Unraveling the Molecular Mechanisms and Vulnerabilities of Colorectal Cancer: A Step Forward in Target Discovery. Marcin Duleba, Ryvu Therapeutics, Krakow, Poland.

A163: Exoribonuclease XRN1 is a Therapeutic Vulnerability in Tumors with Intrinsically Elevated Type I Interferon Signaling. Maureen Lynes, Accent Therapeutics, Lexington, MA United States.


A165: FGFR alterations in pediatric cancers: Opportunity for targeted therapy. Ivan Li, Tufts University, Medford, MA United States.


A167: Cellular fitness of MYC-driven cancer cells to genetic and pharmacologic perturbations in normoxia, hypoxia and 3D culture. Jun Yang, St Jude Children's Research Hospital, Memphis, TN United States.

A168: T cell receptor-based bispecific molecules targeting KRAS neoantigen cancer driver mutations. Andrew D. Whale, Immunocore Ltd, Oxford, United Kingdom.


A170: Discovery of Small Molecule Inhibitors of ADAR1. Shane M. Buker, Accent Therapeutics, Lexington, MA United States.

A172: TP-317, a first-in-class resolvin E1 small molecule, drives adjuvant efficacy in solid tumors by engaging innate and adaptive anti-tumor immunity in the tumor microenvironment (TME) and has neoadjuvant potential. John F. Parkinson, Thetis Pharmaceuticals, Danbury, CT United States.


A176: Loss of SMAD4 unleashes mTOR and increases dependency on cap-dependent translation in esophageal tumorigenesis. Nicholas J. Clemons, Peter MacCallum Cancer Centre, Melbourne, VIC Australia.
A177: *In vivo TuBa-seq Growth Profiling Identifies a Differential Role of the Tbx2 Subfamily in Oncogene-Negative Versus Kras-driven Lung Cancers.* Athar Khalil, Case Western Reserve University, Cleveland Heights, OH United States.

A178: *Therapeutic potential of a p14ARF minimal domain peptide in non-small cell lung cancer.* Anna L. Grobelny, Washington University, St. Louis, MO United States.